Neurografix v. United States

111 Fed. Cl. 501, 2013 U.S. Claims LEXIS 617, 2013 WL 2469079
CourtUnited States Court of Federal Claims
DecidedJune 7, 2013
Docket12-385C
StatusPublished
Cited by3 cases

This text of 111 Fed. Cl. 501 (Neurografix v. United States) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Neurografix v. United States, 111 Fed. Cl. 501, 2013 U.S. Claims LEXIS 617, 2013 WL 2469079 (uscfc 2013).

Opinion

*503 OPINION AND ORDER OF DISMISSAL

EDWARD J. DAMICH, Judge

NeuroGrafix (“NG”), Neurography Institute Medical Associates, Inc. (“NIMA”), and Image-Based Surgieenter Corp. (“IBS”) (collectively, “Plaintiffs”) brought this suit alleging that the Defendant (“United States” or “Government”) has made unauthorized use of U.S. Patent No. 5,560,360 (the “’360 Patent”). The ’360 Patent relates to the field of magnetic resonance imaging (“MRI”). 2 The United States has moved to dismiss the Complaint for lack of jurisdiction on the ground that the Plaintiffs lack standing. For the reasons that follow, the motion is GRANTED.

I. Background

a. Allegations in the Complaint

The ’360 Patent was issued on October 1, 1999. The University of Washington (“UW”), a public institution of higher education, is the owner by assignment of the ’360 Patent. According to the Complaint, the Washington Research Foundation (“WRF”) holds substantially all rights in the ’360 Patent via exclusive license from UW. In turn, WRF allegedly licensed substantially all rights in the Patent to NG in December of 1998.

The Complaint alleges that the rights in the ’360 Patent have been divided into three fields of medicine via sublicenses from NG to NIMA and NIMA to IBS. NG is currently the exclusive licensee of the Patent in the field of non-human, non-surgical medicine. NIMA is the exclusive licensee in the field of human, non-surgical medicine. Finally, IBS is the exclusive licensee in the field of human, surgical medicine. Plaintiffs allege that they “have a legal right to enforce their rights under the patent, sue for infringement, and seek all available relief and damages.”

The Plaintiffs claim that the Government, through the Department of Defense, the Department of Veterans Affairs, and possibly through a number of other departments and agencies, has infringed the ’360 Patent. Specifically, the Plaintiffs claim that the Government has infringed the ’360 Patent through “the performance of and provision of equipment and methods for peripheral nerve MR Neurography, diffusion anisotropy based traetography and DTI.” Compl. at 4.

b. The Motion and Procedural Posture

The Government moved this Court to dismiss the complaint for lack of jurisdiction. Generally put, the Government asserted that nothing in the Complaint proved that UW— via WRF — has transferred sufficient rights in the ’360 Patent to the Plaintiffs to establish their standing to bring suit. The motion was initially filed in November of 2012.

Plaintiffs filed a response to the motion on December 17, 2012. Along with the response, Plaintiffs filed three sealed documents: a license between WRF and NG (the “WRF-NG Agreement”); a license between *504 NG and NIMA; and a license between NIMA and IBS. In its reply, the Government observed that the ’360 Patent is not mentioned anywhere in the WRF-NG Agreement. 3 It also observed that the WRF-NG Agreement was silent on the transfer to NG of the right to sue the Government. Plaintiffs then filed for leave to submit a sur-reply in response to new arguments raised by the Government. Leave was granted and the sur-reply was filed on January 17, 2013. Because it was the Government’s motion, the Court decided that fairness required it be allowed the last word. Thus, on January 24, 2013, the Government filed a supplemental brief in response to the sur-reply.

After reviewing all of the filings, questions remained in the Court’s mind as to whether jurisdiction was appropriate in this case. To this end, the Court ordered that Plaintiff submit certain additional evidence, which is described in further detail in the Court’s February 5, 2013 Order. The documents submitted in response to that order include, inter alia: a Technology Administration Agreement between St. George’s Hospital Medical School, 4 UW and WRF; an agreement between UW and WRF (the “UW-WRF Agreement”); and the original 1998 agreement between WRF and NG. 5 Once again, the Government moved for leave to file a brief addressing Plaintiffs’ new submissions, and the Court obliged. The Government’s second supplemental brief was submitted on February 22, 2013.

II. Legal Standard

a. Rule 12(b)(1) Motions

A motion brought under Rules of the Court of Federal Claims (“RCFC”) Rule 12(b)(1) challenges the Court’s subject matter jurisdiction. See RCFC 12(b)(1). Standing is jurisdictional. See Hoopa Valley Tribe v. United States, 597 F.3d 1278, 1283 (Fed.Cir.2010); see also Myers Investigative and Security Services, Inc. v. United States, 275 F.3d 1366, 1369 (Fed.Cir.2002) (“[Sjtanding is a threshold jurisdictional issue.”). “The party invoking federal jurisdiction bears the burden of establishing [the] elements [of standing.]” Lujan v. Defenders of Wildlife, 504 U.S. 555, 561, 112 S.Ct. 2130, 119 L.Ed.2d 351 (1992).

b. 28 U.S.C. § 1498(a)

The Court of Federal Claims’ jurisdiction over claims of governmental patent infringement is established by 28 U.S.C. § 1498(a). Pursuant to § 1498(a), the “owner” of a patent may bring suit against the Government to recover the owner’s “reasonable and entire” compensation for the Government’s use of the owner’s invention. 28 U.S.C. § 1498(a). In order to qualify as an “owner,” a plaintiff proceeding under § 1498(a) must have an interest equal to that which would support a lawsuit against a private defendant. See E.W. Bliss Co. v. United States, 253 U.S. 187, 191-92, 40 S.Ct. 455, 64 L.Ed. 852 (1920). This means that case law on the standing of a “patentee” to sue under 35 U.S.C. § 281 is instructive for purposes of determining whether a plaintiff in this Court is an “owner” for the purposes of § 1498(a).

The Federal Circuit has explained that there are three categories of standing for a potential plaintiff in patent eases: (1) those that hold all substantial rights in the patent; (2) those that hold exclusionary rights granted by the patent, but not all substantial rights in the patent; and (3) those that do not even hold exclusionary rights under the patent. Morrow v. Microsoft Corp.,

Related

Aaron G. Filler
U.S. Tax Court, 2021
Filler v. United States
Federal Claims, 2020
In re Neurografix ('360) Patent Litigation
5 F. Supp. 3d 146 (D. Massachusetts, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
111 Fed. Cl. 501, 2013 U.S. Claims LEXIS 617, 2013 WL 2469079, Counsel Stack Legal Research, https://law.counselstack.com/opinion/neurografix-v-united-states-uscfc-2013.